134 related articles for article (PubMed ID: 31680085)
1. Clinical efficacy and safety of benzbromarone in elderly hypertensive patients with hyperuricemia.
Gao H
Pak J Pharm Sci; 2019 Jul; 32(4(Supplementary)):1869-1871. PubMed ID: 31680085
[TBL] [Abstract][Full Text] [Related]
2. Safety and Efficacy of Benzbromarone and Febuxostat in Hyperuricemia Patients with Chronic Kidney Disease: A Prospective Pilot Study.
Yu H; Liu X; Song Y; Cheng J; Bao H; Qin L; Zhou X; Wang L; Peng A
Clin Exp Nephrol; 2018 Dec; 22(6):1324-1330. PubMed ID: 29761242
[TBL] [Abstract][Full Text] [Related]
3. Randomized, Open-Label, Cross-Over Comparison of the Effects of Benzbromarone and Febuxostat on Endothelial Function in Patients with Hyperuricemia.
Nakata T; Ikeda S; Koga S; Yonekura T; Tsuneto A; Doi Y; Fukae S; Minami T; Kawano H; Maemura K
Int Heart J; 2020 Sep; 61(5):984-992. PubMed ID: 32921665
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of benzbromarone in hyperuricemic patients associated with chronic kidney disease.
Fujimori S; Ooyama K; Ooyama H; Moromizato H
Nucleosides Nucleotides Nucleic Acids; 2011 Dec; 30(12):1035-8. PubMed ID: 22132953
[TBL] [Abstract][Full Text] [Related]
5. Is hyperuricemia a risk factor for arteriosclerosis? Uric acid and arteriosclerosis in apolipoprotein e-deficient mice.
Wakuda H; Uchida S; Ikeda M; Tabuchi M; Akahoshi Y; Shinozuka K; Yamada S
Biol Pharm Bull; 2014; 37(12):1866-71. PubMed ID: 25451835
[TBL] [Abstract][Full Text] [Related]
6. Letter by George regarding article, "Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled cross-over preliminary study".
George J
Circ Heart Fail; 2010 May; 3(3):e10; author reply e14. PubMed ID: 20484184
[No Abstract] [Full Text] [Related]
7. Effective uric acid-lowering treatment for hypertensive patients with hyperuricemia.
Ohta Y; Ishizuka A; Arima H; Hayashi S; Iwashima Y; Kishida M; Yoshihara F; Nakamura S; Kawano Y
Hypertens Res; 2017 Mar; 40(3):259-263. PubMed ID: 27760998
[TBL] [Abstract][Full Text] [Related]
8. Benzbromarone as a possible cause of acute kidney injury in patients with urolithiasis: Two case reports.
Ye X; Wu J; Tang K; Li W; Xiong C; Zhuo L
Medicine (Baltimore); 2019 Apr; 98(15):e15214. PubMed ID: 30985721
[TBL] [Abstract][Full Text] [Related]
9. Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study.
Ogino K; Kato M; Furuse Y; Kinugasa Y; Ishida K; Osaki S; Kinugawa T; Igawa O; Hisatome I; Shigemasa C; Anker SD; Doehner W
Circ Heart Fail; 2010 Jan; 3(1):73-81. PubMed ID: 19933411
[TBL] [Abstract][Full Text] [Related]
10. Dotinurad versus benzbromarone in Japanese hyperuricemic patient with or without gout: a randomized, double-blind, parallel-group, phase 3 study.
Hosoya T; Sano T; Sasaki T; Fushimi M; Ohashi T
Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):62-70. PubMed ID: 31980978
[TBL] [Abstract][Full Text] [Related]
11. Relationship between serum allantoin and urate in healthy subjects and effects of benzbromarone in gout patients.
Kurajoh M; Koyama H; Shoji T; Sumida C; Yamamoto A; Tsutsumi Z; Moriwaki Y; Yamamoto T; Koga M
Int J Clin Pharmacol Ther; 2012 Apr; 50(4):265-71. PubMed ID: 22456297
[TBL] [Abstract][Full Text] [Related]
12. Fulminant hepatic failure associated with benzbromarone treatment: a case report.
Arai M; Yokosuka O; Fujiwara K; Kojima H; Kanda T; Hirasawa H; Saisho H
J Gastroenterol Hepatol; 2002 May; 17(5):625-6. PubMed ID: 12084041
[No Abstract] [Full Text] [Related]
13. Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients.
Reinders MK; van Roon EN; Houtman PM; Brouwers JR; Jansen TL
Clin Rheumatol; 2007 Sep; 26(9):1459-65. PubMed ID: 17308859
[TBL] [Abstract][Full Text] [Related]
14. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout.
Reinders MK; Haagsma C; Jansen TL; van Roon EN; Delsing J; van de Laar MA; Brouwers JR
Ann Rheum Dis; 2009 Jun; 68(6):892-7. PubMed ID: 18633127
[TBL] [Abstract][Full Text] [Related]
15. Uricosuric medications for chronic gout.
Kydd AS; Seth R; Buchbinder R; Edwards CJ; Bombardier C
Cochrane Database Syst Rev; 2014 Nov; (11):CD010457. PubMed ID: 25392987
[TBL] [Abstract][Full Text] [Related]
16. Uric acid-lowering therapy with benzbromarone in hypertension with asymptomatic hyperuricemia: a randomized study focusing left ventricular diastolic function.
Ke J; Pan J; Lin H; Han Z; Gu J
Curr Med Res Opin; 2023 Jul; 39(7):947-953. PubMed ID: 37300510
[TBL] [Abstract][Full Text] [Related]
17. Comparative effectiveness of allopurinol, febuxostat and benzbromarone on renal function in chronic kidney disease patients with hyperuricemia: a 13-year inception cohort study.
Chou HW; Chiu HT; Tsai CW; Ting IW; Yeh HC; Huang HC; Kuo CC;
Nephrol Dial Transplant; 2018 Sep; 33(9):1620-1627. PubMed ID: 29165620
[TBL] [Abstract][Full Text] [Related]
18. [Assessment on the clinical efficacy and safety of xiezhuo chubi recipe in treating hyperuricemia].
Zhang XX; Sun WF; Xu W
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2011 Sep; 31(9):1216-9. PubMed ID: 22013799
[TBL] [Abstract][Full Text] [Related]
19. Risk factors associated with renal lithiasis during uricosuric treatment of hyperuricemia in patients with gout.
Perez-Ruiz F; Hernandez-Baldizon S; Herrero-Beites AM; Gonzalez-Gay MA
Arthritis Care Res (Hoboken); 2010 Sep; 62(9):1299-305. PubMed ID: 20506124
[TBL] [Abstract][Full Text] [Related]
20. Stopping progression in familial juvenile hyperuricemic nephropathy with benzbromarone?
Lhotta K
Kidney Int; 2003 Nov; 64(5):1920-1. PubMed ID: 14531831
[No Abstract] [Full Text] [Related]
[Next] [New Search]